Stockreport

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Cullinan Oncology, Inc.  (CGEM) 
PDF Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients wi [Read more]